Proposed $1.6m US-Funded Vaccine Trial Cancelled in Guinea-Bissau
A $1.6 million US-funded vaccine trial in Guinea-Bissau was cancelled following ethical concerns over withholding standard medical care from newborns and a…

A proposed clinical trial involving the administration of hepatitis B vaccines to newborns in Guinea-Bissau has been cancelled following significant regulatory and ethical opposition. The study, which received $1.6 million in funding from the United States in December 2025, aimed to enroll 14,000 infants to evaluate the broader health effects of the vaccine. The research design involved withholding the vaccine from half of the participants, a methodology that drew sharp criticism from international health authorities.
The World Health Organization (WHO) formally challenged the trial, citing ethical concerns regarding the withholding of a proven, life-saving intervention. In Guinea-Bissau, where hepatitis B prevalence is high, the standard of care currently delays vaccination until six weeks of age. The WHO and local health officials are now working to accelerate rollout of birth-dose vaccinations to early 2026, ahead of the previously scheduled 2028 implementation.
Government officials in Guinea-Bissau prohibited the trial in Government officials in Guinea-Bissau prohibited the trial in January, citing a lack of transparency and failure to secure proper local authorization. Despite claims from the sponsoring university that the project had received necessary ethical approvals, health ministry maintained that the study lacked official consent. The dispute escalated in October when local judicial police conducted a search of the research facility and seized the vaccine supply.
This incident highlights growing geopolitical sensitivities regarding medical research conducted by foreign entities in developing nations. Critics have characterized the trial’s design as exploitative, questioning why such research was not conducted in the sponsoring country. The cancellation underscores the increasing scrutiny of international clinical trials and the necessity for rigorous alignment with local regulatory frameworks and global health standards to maintain institutional credibility and public trust.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Energy drinks show 11-fold cardiac-arrest reporting signal
- Children with higher ultra-processed intake show stronger reward signals
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

